HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00304655

Long-term aripiprazole for psychosis

About this title

Read the official source —

This study evaluated the safety and effectiveness of Aripiprazole for people with schizophrenia.

Medication studyAges 18–65South Korea
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the safety and effectiveness of Aripiprazole for people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Listed locations
SeoulSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study clarity

Study information

Study start dateJuly 2004
Recruitment status
Completed
Enrollment listed in the registry
300
Sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Sponsor type
Pharmaceutical company
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
South Korea
Age range
From 18 Years to 65 Years
Official registry ID
NCT00304655
Official title
Show the full official title

Multicenter, Single Group Study of Aripiprazole Efficacy and Safety in the Acute Psychosis Treatment of Schizophrenia, Schizophreniform Disorder and Schizoaffective Disorder.

Looking for a study you can join?

Explore recruiting studies

Get this study by email

HopeStage may email me about this study.
Loading the security check...

Recruitment & locations

Completed

Seoul

Checked Official study record (opens in a new tab)
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the safety and effectiveness of Aripiprazole for people with schizophrenia.

Who is behind this study?

The study sponsor is Korea Otsuka Pharmaceutical Co., Ltd., a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Aripiprazole.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies